Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivastigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 1.00 |
| ▸ | BCHE known ✓ | P06276 | 11/20 | 1.00 |
| ▸ | MARK4 | Q96L34 | 1/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.86 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivastigmine SCHEMBL25232361 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL2763 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL3978590 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL29612619 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL30064255 | 1.00 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL13841811 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL29614698 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL1170429 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL6382107 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA | |
| Rivastigmine SCHEMBL6382629 | 0.93 | ACHE (1.00) | ACHEBCHEMARK4FAAHMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4548926-A1 | Y-SECRETASE INHIBITOR, AB-PEPTIDE PRODUCTION INHIBITOR, AND PHARMACEUTICAL | Tohoku University (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20250099459-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-03-27 | — | — | US | disclosed |
| WO-2024238387-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO., LTD. (KR) | 2024-11-21 | — | — | WO | disclosed |
| CN-118401123-A | Brain function improving agent | 国立大学法人大阪大学 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024036005-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO., LTD. (KR) | 2024-02-15 | — | — | WO | disclosed |
| US-20230172880-A1 | FAST-ACTING TOPICAL ANESTHETIC FORMULATIONS | ACHELON, LLC | 2023-06-08 | — | — | US | disclosed |
| EP-4138806-A1 | FAST-ACTING TOPICAL ANESTHETIC FORMULATIONS | Achelon, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| EP-3610879-B9 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF ALZHEIMER'S DISEASE | GLOVIA COMPANY LTD (JP) | 2023-01-25 | — | — | EP | disclosed |
| US-20220370442-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-11-24 | — | — | US | disclosed |
| EP-3610879-B1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF ALZHEIMER'S DISEASE | GLOVIA COMPANY LTD (JP) | 2022-11-09 | — | — | EP | disclosed |
| CN-114712360-A | Prophylactic and/or therapeutic agent comprising epiprazole or salt thereof | 大塚制药株式会社 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370442-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | SLC6A3, SLC6A2, SNCA | ACHE 104/4885BCHE 140/4885MARK4 409/4885 |
| US-20250099459-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | SLC6A3, SLC6A2, SNCA | ACHE 104/4885BCHE 140/4885MARK4 409/4885 |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | IL2, PBK, IL2RA | ACHE 99/4885BCHE 126/4885MARK4 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.